• Product NameAZD9291
• Brief DescriptionInhibitors
• Purification99.55%
• Biological ActivityAZD9291 is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
• Target NameEGFR inhibitor
• CAS No. 1421373-65-0
• Calculated MW 499.61
• Formulation C28H33N7O2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=CC=CC=C23)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
  Pathways:Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
  Receptor:EGFR (Exon 19 deletion); EGFR (L858R/T790M )
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 43 mg/mL warmed (86.06 mM); DMSO: 99 mg/mL warmed (198.15 mM)
  Appearance:Yellow Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Patent. 2013, WO2013014448 A1.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting